This includes exogenous supplementation of ACE2 by administering human recombinant soluble ACE2 (hrsACE2), which proved not only to inhibit SARS-CoV-2 infection in a laboratory model, but also to impede the COVID-19-related ACE2 depletion, and thus prevent endothelial dysfunction. The gene discussed is ACE2; the disease is COVID-19.